| Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. | |
| | |
MedLine Citation:
|
PMID: 20950379 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Risk of Type 2 diabetes varies by ethnicity, but whether ethnicity remains important among those who have impaired glucose tolerance or impaired fasting glucose is uncertain. Whether the effect of thiazolidinedione treatment on diabetes prevention in persons with non-diabetic dysglycaemia varies by ethnicity is also not known. We addressed these questions using data collected in the DREAM trial. METHODS: A 2-by-2 factorial double-blind randomized controlled trial to compare the effects of rosiglitazone and ramipril on the primary outcome of diabetes or death in persons meeting criteria for impaired glucose tolerance or impaired fasting glucose. The effect of these interventions by ethnicity was estimated using Cox regression analysis. RESULTS: Of 5269 adults, 2365 were randomly assigned to rosiglitzone and 2634 to placebo. South Asians showed a higher hazard for the primary outcome compared with Europeans (hazard ratio, 95% confidence interval 2.21, 1.41-3.47) adjusted for age, gender, BMI, waist-hip ratio and geographic region. A lesser increase in risk was seen in Black people (1.37, 1.04-1.81). A significant reduction in risk of the primary outcome with rosiglitazone treatment assignment was seen in all ethnic groups, but the treatment effect significantly differed by ethnicity (P=0.0242), with South Asians experiencing a smaller, and Latinos a larger preventive effect. CONCLUSIONS: Ethnicity is an important risk factor for Type 2 diabetes in dysglycaemic persons. All ethnic groups experienced a large significant reduction in diabetes risk because of rosiglitazone. The magnitude of this reduction differed by ethnicity. Given the post hoc nature of this analysis, further confirmation of these findings is needed. |
| | |
Authors:
|
E J Boyko; H C Gerstein; V Mohan; S Yusuf; P Sheridan; S Anand; J E Shaw; |
Related Documents
:
|
18378359 - Vascular risk factors and dementia in the general population aged >85 years: prospectiv... 19787289 - Excessive maternal transmission of diabetes in japanese families with young-onset type ... 7872389 - Incidence of cataract surgery in the wisconsin epidemiologic study of diabetic retinopa... 16108859 - Relative role of major risk factors for type 2 diabetes development in the historical c... 16766779 - Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic pat... 20548009 - White rice, brown rice, and risk of type 2 diabetes in us men and women. 8018009 - Normal insulin-like growth factor-i in an elderly woman with acromegaly and medical ill... 8758019 - Insulin resistance and development of diabetes mellitus associated with megestrol aceta... 2838359 - Evidence for initial involvement of macrophage in development of insulitis in nod mice. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetic medicine : a journal of the British Diabetic Association Volume: 27 ISSN: 1464-5491 ISO Abbreviation: Diabet. Med. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-18 Completed Date: 2011-01-07 Revised Date: 2011-02-25 |
Medline Journal Info:
|
Nlm Unique ID: 8500858 Medline TA: Diabet Med Country: England |
Other Details:
|
Languages: eng Pagination: 1226-32 Citation Subset: IM |
Copyright Information:
|
© 2010 The Authors. Diabetic Medicine © 2010 Diabetes UK. |
Affiliation:
|
VA Puget Sound Health Care System, Seattle, WA, USA. eboyko@u.washington.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2
/
drug therapy,
epidemiology,
ethnology*,
prevention & control Drug Therapy, Combination Female Glucose Intolerance / drug therapy, epidemiology, ethnology* Humans Hyperglycemia / drug therapy, epidemiology, ethnology* Hypoglycemic Agents / therapeutic use* Incidence Male Middle Aged Ramipril / therapeutic use Risk Assessment Thiazolidinediones / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
MCT41548//Canadian Institutes of Health Research |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Thiazolidinediones; 122320-73-4/rosiglitazone; 87333-19-5/Ramipril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Telephone follow-up to improve glycaemic control in patients with Type 2 diabetes: systematic review...
Next Document: Trends of diabetes according to body mass index levels in Iran: results of the national Surveys of R...